Chemed Corporation $CHE Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale raised its holdings in shares of Chemed Corporation (NYSE:CHE) by 0.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 155,267 shares of the company’s stock after buying an additional 688 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Chemed were worth $75,604,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Alpine Bank Wealth Management acquired a new position in shares of Chemed in the 1st quarter worth $29,000. HM Payson & Co. acquired a new position in shares of Chemed in the 1st quarter valued at $30,000. SVB Wealth LLC purchased a new position in Chemed in the 1st quarter worth about $30,000. WPG Advisers LLC acquired a new stake in Chemed during the 1st quarter worth about $32,000. Finally, Geneos Wealth Management Inc. lifted its stake in Chemed by 330.4% during the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Wall Street Analyst Weigh In

CHE has been the topic of several analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and boosted their target price for the company from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Royal Bank Of Canada reduced their target price on Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Bank of America lowered their price target on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Finally, Oppenheimer dropped their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Chemed currently has a consensus rating of “Moderate Buy” and an average target price of $578.50.

Insider Transactions at Chemed

In other news, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the sale, the director directly owned 3,397 shares in the company, valued at $1,574,135.83. The trade was a 4.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George J. Walsh III acquired 200 shares of the company’s stock in a transaction that occurred on Monday, August 4th. The stock was purchased at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the acquisition, the director directly owned 3,523 shares of the company’s stock, valued at $1,469,443.30. The trade was a 6.02% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 13,162 shares of company stock valued at $5,677,511 in the last quarter. Corporate insiders own 3.29% of the company’s stock.

Chemed Stock Down 0.7%

CHE stock opened at $441.75 on Wednesday. The company has a 50 day moving average of $449.11 and a two-hundred day moving average of $501.36. The company has a market cap of $6.44 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 2.59 and a beta of 0.43. Chemed Corporation has a 12-month low of $408.42 and a 12-month high of $623.60.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). Chemed had a return on equity of 25.83% and a net margin of 11.56%.The company had revenue of $618.80 million during the quarter, compared to analyst estimates of $650.60 million. During the same period last year, the company posted $5.47 earnings per share. The company’s revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, research analysts anticipate that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were paid a dividend of $0.60 per share. This is a boost from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend was Monday, August 11th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is 12.34%.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.